2,3-Dehydrosilybin A
CAS : 25166-14-7
Ref. 3D-ABA16614
1mg | Arrêté | ||
2mg | Arrêté | ||
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté |
Informations sur le produit
- 4H-1-Benzopyran-4-one, 2-[2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]-3,5,7-trihydroxy-, (2R-trans)-
- 2-[(2R,3R)-2,3-Dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]-3,5,7-trihydroxy-4H-1-benzopyran-4-one
- 4H-1-Benzopyran-4-one, 2-[(2R,3R)-2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]-3,5,7-trihydroxy-
- Chromone, 3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxan-6-yl]-
- 2,3-Dehydrosilymarin
2,3-Dehydrosilybin A is a compound that produces a redox signal in cells. It has been shown to inhibit glutamate dehydrogenase and protein homeostasis, leading to cell death. 2,3-Dehydrosilybin A also induces autophagy and inhibits the cell cycle at G2/M phase. This compound has been shown to have an anti-cancer effect on human cancer cells in culture and may be useful in treating cancers with metabolic defects such as cancer cachexia.